Key Highlights

  • PDS Biotechnology shares closed up 35% at $0.40.
  • The company completed the initial closing of an approximately $11.3 million PIPE led by Nant Capital.
  • A further $11.0 million milestone closing is tied to submission of a registrational Phase 3 PDS0301 protocol to the FDA.
  • NantWorks receives a one-year exclusive negotiation right for PDS0101, and Dr. Patrick Soon-Shiong joins the board.

PDS Biotechnology Corporation (NASDAQ: PDSB) shares closed up 35% at $0.40 after the company completed the initial closing of an approximately $11.3 million PIPE led by Nant Capital.

What Happened

A further $11.0 million milestone closing is tied to submission of a registrational Phase 3 PDS0301 protocol to the FDA, adding Capital to repay Debt and support late-stage development. As part of the transaction, NantWorks receives a one-year exclusive negotiation right for PDS0101, and Dr. Patrick Soon-Shiong joins the board.

Market Reaction

Shares rose sharply as investors responded to the new capital, the milestone-linked follow-on funding tied to the PDS0301 Phase 3 protocol, and the added credibility from Dr. Soon-Shiong's board appointment.

Outlook

Submission of the registrational Phase 3 PDS0301 protocol to the FDA, which would trigger the additional $11.0 million milestone closing, represents the next major disclosed step for PDS Biotechnology.